A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Profile

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Sapacitabine (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SEAMLESS
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to a Cyclacel Pharmaceuticals media release, an abstract from the study has been submitted to the American Society of Hematology (ASH), and if accepted, will be the subject of an oral or poster presentation at the 59th ASH Annual Meeting to be held December 9 - 12, 2017.
    • 28 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Cyclacel Pharmaceuticals media release.
    • 28 Mar 2017 According to a Cyclacel Pharmaceuticals media release, the company is analyzing stratified and exploratory subgroups of this trial. Depending on this analysis the Company may initiate discussions with European and U.S. regulators to determine a potential regulatory pathway.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top